These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25488990)

  • 1. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.
    Deng R; Cassady K; Li X; Yao S; Zhang M; Racine J; Lin J; Chen L; Zeng D
    J Immunol; 2015 Jan; 194(2):560-74. PubMed ID: 25488990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
    Fujiwara H; Maeda Y; Kobayashi K; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Chen L; Azuma M; Yagita H; Tanimoto M
    J Immunol; 2014 Sep; 193(5):2565-73. PubMed ID: 25080485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
    Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D
    J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
    Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
    Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DCs sensitized with mPD-L1-Ig fusion protein improve the effect of heart transplantation in mice by promoting the generation of T-reg cells.
    Liu C; Chen H; Jia J; Hong T; Wang C
    Cell Immunol; 2014 Jul; 290(1):169-77. PubMed ID: 24997656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
    Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
    Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
    J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.
    Flies DB; Higuchi T; Chen L
    J Immunol; 2015 Jun; 194(11):5294-304. PubMed ID: 25917101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes.
    Ohnuma K; Hatano R; Aune TM; Otsuka H; Iwata S; Dang NH; Yamada T; Morimoto C
    J Immunol; 2015 Apr; 194(8):3697-712. PubMed ID: 25786689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients.
    Yi T; Li X; Yao S; Wang L; Chen Y; Zhao D; Johnston HF; Young JS; Liu H; Todorov I; Forman SJ; Chen L; Zeng D
    J Immunol; 2011 Mar; 186(5):2739-49. PubMed ID: 21263067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.
    Yarkoni S; Prigozhina TB; Slavin S; Askenasy N
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):523-35. PubMed ID: 22227590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CD80 and CD86 blockade and anti-interleukin-12 treatment on mouse acute graft-versus-host disease.
    Saito K; Yagita H; Hashimoto H; Okumura K; Azuma M
    Eur J Immunol; 1996 Dec; 26(12):3098-106. PubMed ID: 8977310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
    Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
    Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
    Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
    J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
    Ostrand-Rosenberg S; Horn LA; Alvarez JA
    Cancer Immunol Immunother; 2015 Oct; 64(10):1287-93. PubMed ID: 25792524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade.
    Pauken KE; Nelson CE; Martinov T; Spanier JA; Heffernan JR; Sahli NL; Quarnstrom CF; Osum KC; Schenkel JM; Jenkins MK; Blazar BR; Vezys V; Fife BT
    J Immunol; 2015 Apr; 194(8):3551-3555. PubMed ID: 25769925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 serves as a double agent in separating GVL from GVHD.
    Brennan TV; Yang Y
    J Clin Invest; 2017 May; 127(5):1627-1630. PubMed ID: 28414300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.
    Wang L; Han R; Hancock WW
    Eur J Immunol; 2007 Oct; 37(10):2983-90. PubMed ID: 17899549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1/PD-1 signal deficiency promotes allogeneic immune responses and accelerates heart allograft rejection.
    Wang W; Carper K; Malone F; Latchman Y; Perkins J; Fu Y; Reyes J; Li W
    Transplantation; 2008 Sep; 86(6):836-44. PubMed ID: 18813109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.